skip to the content

Clinical Trials

Systemic Lupus Erythematosus - Clinical Trial (08-02-145)

A Phase 2, Multi-Center, Randomized, Open Label, Trial to Evaluate the Safety, Tolerability, and Biological Activity of 2 Dosing Schedules of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monocolonal Anti-BLyS Antibody, Administered Subcutaneously to Subjects with Systemic Lupus Erythematosus (SLE)

Protocol ID

08-02-145

Protocol Description

Lupus is a chronic, inflammatory autoimmune disorder. It may affect the skin, joints, kidneys, and other organs. Lupus can cause joint pain, arthritis, inflammation of organs, skin rashes, sensitivity to light, muscle aches, seizures, and chest pain.

The purpose of this study is to test the safety and effectiveness of an experimental drug called belimumab. We want to find out whether it is effective, and if so, how effective it is in people with lupus. This study will look at how people react to and how the body uses belimumab at different doses.

Eligibility Criteria

Patients with systemic lupus erythematosus

Primary Investigator(s)

  • Richard Furie, MD

Contact Information

Michelle Kong
(516) 708-2557
mkong@nshs.edu

Last Update

December 3, 2009
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Lupus:
top
top